Literature DB >> 16297162

Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.

N Dhiman1, I G Ovsyannikova, J E Ryan, R M Jacobson, R A Vierkant, V S Pankratz, S J Jacobsen, G A Poland.   

Abstract

Immunity to measles is conferred by the interplay of humoral and cellular immune responses, the latter being critical in maintaining long-term recall response. Therefore, it is important to evaluate measles-specific humoral and cellular immunity in populations several years after vaccination and understand the correlations among these measures of immunity. We examined measles-specific antibodies, lymphoproliferation and the Th1/Th2 signature cytokines, interferon (IFN)-gamma and interleukin (IL)-4, in a population-based cohort of healthy children from Olmsted County, Minnesota after two doses of measles-mumps-rubella-II (MMR-II) vaccine. We detected positive measures of measles-specific cellular and humoral immunity in the majority of our study population. However, a small proportion of subjects demonstrated an immune response skewed towards the Th2 type, characterized by the presence of either IL-4 and/or measles-specific antibodies and a lack of IFN-gamma production. Further, we observed a significant positive correlation between lymphoproliferation and secretion of IFN-gamma (r = 0.20, P = 0.0002) and IL-4 (r = 0.15, P = 0.005). Measles antibody levels were correlated with lymphoproliferation (r = 0.12, P = 0.03), but lacked correlation to either cytokine type. In conclusion, we demonstrated the presence of both long-term cellular and humoral responses after MMR-II vaccination in a significant proportion of study subjects. Further, a positive correlation between lymphoproliferation and IL-4 and IFN-gamma suggests that immunity to measles may be maintained by both Th1 and Th2 cells. We speculate that the Th2 biased response observed in a subset of our subjects may be insufficient to provide long-term immunity against measles. Further examination of the determinants of Th1 versus Th2 skewing of the immune response and long-term follow-up is needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297162      PMCID: PMC1809549          DOI: 10.1111/j.1365-2249.2005.02931.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Fatal measles pneumonia without rash in a child with AIDS.

Authors:  L E Markowitz; F W Chandler; E O Roldan; M J Saldana; K C Roach; S S Hutchins; S R Preblud; C D Mitchell; G B Scott
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

2.  Measles as an index of immunological function.

Authors:  F M Burnet
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

3.  Immunosuppression after measles vaccination.

Authors:  L Smedman; A Joki; A P da Silva; M Troye-Blomberg; B Aronsson; P Perlmann
Journal:  Acta Paediatr       Date:  1994-02       Impact factor: 2.299

Review 4.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Measles virus-induced modulation of host-cell gene expression.

Authors:  Gert Bolt; Kurt Berg; Merete Blixenkrone-Møller
Journal:  J Gen Virol       Date:  2002-05       Impact factor: 3.891

6.  Impact of measles virus dendritic-cell infection on Th-cell polarization in vitro.

Authors:  Ingo M Klagge; Marion Abt; Bianca Fries; Sibylle Schneider-Schaulies
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

7.  Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.

Authors:  B J Ward; N Boulianne; S Ratnam; M C Guiot; M Couillard; G De Serres
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

8.  Measles outbreak epidemiology in the United States, 1993-2001.

Authors:  Fuyuen Y Yip; Mark J Papania; Susan B Redd
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

9.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Gamma interferon expression and major histocompatibility complex induction during measles and vesicular stomatitis virus infections of the brain.

Authors:  N Gogate; M Bakhiet; K Kristensson; E Norrby; T Olsson
Journal:  J Neuroimmunol       Date:  1991-01       Impact factor: 3.478

View more
  14 in total

1.  Independence of measles-specific humoral and cellular immune responses to vaccination.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2012-03-03       Impact factor: 2.850

2.  Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Authors:  Benjamin J Umlauf; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

3.  Consistency of HLA associations between two independent measles vaccine cohorts: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-25       Impact factor: 3.641

4.  Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

5.  Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results.

Authors:  Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; Jenna E Ryan; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

6.  Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Megan M O'Byrne; Robert M Jacobson; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-20       Impact factor: 3.641

7.  Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Neelam Dhiman; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

8.  Response surface methodology to determine optimal measles-specific cytokine responses in human peripheral blood mononuclear cells.

Authors:  Matthew J Taylor; Iana H Haralambieva; Robert A Vierkant; Inna G Ovsyannikova; Gregory A Poland
Journal:  J Immunol Methods       Date:  2012-06-13       Impact factor: 2.303

9.  Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes.

Authors:  Sarah J White; Iana H Haralambieva; Inna G Ovsyannikova; Robert A Vierkant; Megan M O'Byrne; Gregory A Poland
Journal:  Hum Immunol       Date:  2012-04-12       Impact factor: 2.850

Review 10.  Vaccinations in juvenile chronic inflammatory diseases: an update.

Authors:  Clovis A Silva; Nadia E Aikawa; Eloisa Bonfa
Journal:  Nat Rev Rheumatol       Date:  2013-07-02       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.